{
    "nctId": "NCT06240195",
    "briefTitle": "Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study",
    "officialTitle": "Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Biomolecular investigations conducted on multiple platforms",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years;\n* Histological diagnosis of TNBC;\n* Locally advanced unresectable or metastatic disease;\n* Indication for treatment with SG in monotherapy according to clinical practice (patients pre-treated with at least two lines of systemic therapy, of which at least one in an advanced stage);\n* Availability of at least one tumor tissue sample (from primary tumor or metastasis) to be sent to the coordinating center (IRE);\n* Written informed consent;\n* Availability to comply with the procedures established by the protocol, according to the methods and times described.\n\nExclusion Criteria:\n\n* Patients with a history of other malignancies;\n* Contraindications to the use of sacituzumab govitecan SG;\n* Untreated and/or clinically unstable (symptomatic) brain metastases.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}